CXCL9 and metabolic dysfunction-associated steatohepatitis: Our research group has previously demonstrated that DM509 treatment to non-alcoholic steatohepatitis mice decreased liver CXCR3, CXCL9, CXCL10, TNFα, IL-1β, and TGF-β expression (23).